看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。 b; w o+ l2 T& y
3 |" A! B) G1 g4 k
( i& b3 I5 {) Z. D! u: MCurrently available feasibility data for possible combination strategies.
1 e- W: I. q; M————————————————————————————————8 e) y: V) l+ ~5 h1 l9 R1 w
Combination Feasibility according to preliminary data $ D: Q5 d& j' M- r6 Q" l9 k
——————————————————————————————————. P, s! t: @5 V, r
Bevacizumab + sorafenib Yes, reduced dose 6 c" X+ W7 V% V: c% Y
Bevacizumab + sunitinib† No * P" Y6 ^( [* k6 P2 \
Bevacizumab + temsirolimus Yes 2 X0 }6 k# L' y% F
Bevacizumab + everolimus Yes
8 h) K4 l( ~- X. J e; aSorafenib + sunitinib ?
b' z9 T# O/ E# @Sorafenib + temsirolimus Yes, reduced dose
% n8 g+ |' i1 C; L# p/ }Sorafenib + everolimus Yes, reduced dose
, O+ w+ m0 b8 k3 i7 M8 `: P5 qSunitinib + temsirolimus† No
) t; E: y( u9 t0 ?+ z! {: M' z& MSunitinib + everolimus ? ' G( z- Z0 h; a+ m) N* t# y
Temsirolimus + everolimus ?
2 S0 \1 C: V6 [3 q————————————————————7 v) o* P; \9 ~6 g6 L
†Led to US FDA warning.
: ^; S( R, C$ i {$ e! Z8 y?: As yet unattempted combination.+ x( G9 ?3 i; ~) o: M5 Z
|